GT200900014A - Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio. - Google Patents

Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.

Info

Publication number: GT200900014A
Authority: GT; Guatemala
Prior art keywords: succume; cyclopropylpenhylmethyl; glucopiranosil; indoly; conveyors
Prior art date: 2006-07-27

Application number

GT200900014A

Other languages

English (en)

Inventor

Suminiro Nomura

Shigeki Sakamaki

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-27

Filing date

2009-01-22

Publication date

2010-02-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-22 Application filed filed Critical

2010-02-09 Publication of GT200900014A publication Critical patent/GT200900014A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

GT200900014A 2006-07-27 2009-01-22 Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio. GT200900014A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82060406P	2006-07-27	2006-07-27
US88617807P	2007-01-23	2007-01-23

Publications (1)

Publication Number	Publication Date
GT200900014A true GT200900014A (es)	2010-02-09

Family

ID=38515468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GT200900014A GT200900014A (es)	2006-07-27	2009-01-22	Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.

Country Status (31)

Country	Link
US (1)	US7851617B2 (es)
EP (1)	EP2049557B1 (es)
JP (1)	JP5102294B2 (es)
KR (1)	KR101179312B1 (es)
CN (1)	CN101501053B (es)
AR (1)	AR062111A1 (es)
AT (1)	ATE501159T1 (es)
AU (1)	AU2007277662B2 (es)
BR (1)	BRPI0715369A2 (es)
CA (1)	CA2658116C (es)
CL (1)	CL2007002197A1 (es)
CO (1)	CO6150170A2 (es)
CR (1)	CR10583A (es)
DE (1)	DE602007013056D1 (es)
DK (1)	DK2049557T3 (es)
EA (1)	EA016819B1 (es)
GT (1)	GT200900014A (es)
HN (1)	HN2009000161A (es)
IL (1)	IL196267A0 (es)
JO (1)	JO2681B1 (es)
MX (1)	MX2009000995A (es)
MY (1)	MY145106A (es)
NO (1)	NO20085337L (es)
NZ (1)	NZ574072A (es)
PE (1)	PE20080522A1 (es)
PL (1)	PL2049557T3 (es)
PT (1)	PT2049557E (es)
TW (1)	TWI418556B (es)
UA (1)	UA92100C2 (es)
UY (1)	UY30506A1 (es)
WO (1)	WO2008013322A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101611032B (zh) *	2006-12-04	2012-07-18	詹森药业有限公司	作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2699285C (en)	2007-09-10	2016-12-13	Ahmed F. Abdel-Magid	Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
CL2008003653A1 (es) *	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
MX2011002166A (es)	2008-08-28	2011-04-07	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,1-triol.
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
AU2010270202B2 (en)	2009-07-10	2014-04-24	Janssen Pharmaceutica Nv	Crystallisation process for 1-(beta-D-glucopyranosyl)-4-methyl-3- [5-(4-fluorophenyl)-2-thienylmethyl] benzene
IN2012DN02711A (es)	2009-09-15	2015-09-11	Janssen Pharmaceutica Nv
IN2012DN03299A (es) *	2009-10-14	2015-10-23	Janssen Pharmaceutica Nv
BR112012008924A2 (pt)	2009-10-20	2019-09-24	Novartis Ag	derivado de glicosídeo e usos do mesmo
EA021983B1 (ru)	2009-11-02	2015-10-30	Пфайзер Инк.	Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
SG185525A1 (en)	2010-05-11	2012-12-28	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
FR2969614A1 (fr) *	2010-12-28	2012-06-29	Sanofi Aventis	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
DK2658844T3 (en)	2010-12-28	2017-02-06	Sanofi Sa	HIS UNKNOWN PYRIMIDINE DERIVATIVES, PREPARING THEREOF AND PHARMACEUTICAL USE THEREOF AS ACTIVE (PKB) PHOSPHORATION INHIBITORS
AU2012241897C1 (en)	2011-04-13	2017-05-11	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of SGLT2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2012162115A2 (en) *	2011-05-20	2012-11-29	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt-2
WO2012162113A1 (en) *	2011-05-20	2012-11-29	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibittors of sglt-2
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8697658B2 (en) *	2011-12-15	2014-04-15	National Health Research Institutes	Glycoside compounds
AR097890A1 (es)	2013-10-17	2016-04-20	Lilly Co Eli	Compuestos de urea
JO3298B1 (ar)	2013-11-01	2018-09-16	Lilly Co Eli	مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP7137318B2 (ja) *	2018-02-22	2022-09-14	オルガノ株式会社	被処理液の精製方法
CN115772163B (zh) *	2022-12-09	2025-07-22	中国科学院成都生物研究所	吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5731292A (en) *	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
US5830873A (en) *	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
WO2001068660A1 (en)	2000-03-17	2001-09-20	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
WO2002053573A1 (en) *	2000-12-28	2002-07-11	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and use thereof in medicines
DE60230591D1 (de)	2001-02-26	2009-02-12	Kissei Pharmaceutical	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
EP1364958B1 (en) *	2001-02-27	2010-09-08	Kissei Pharmaceutical Co., Ltd.	Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
JP2004536047A (ja)	2001-04-11	2004-12-02	ブリストル−マイヤーズ　スクイブ　カンパニー	糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
EP1389621A4 (en)	2001-04-27	2005-05-11	Ajinomoto Kk	N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
WO2003011880A1 (fr)	2001-07-31	2003-02-13	Kissei Pharmaceutical Co., Ltd.	Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
WO2003020737A1 (en)	2001-09-05	2003-03-13	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
US6562791B1 (en) *	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
DE10231370B4 (de) *	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
US7414072B2 (en)	2002-08-09	2008-08-19	Taisho Pharmaceutical Co., Ltd.	Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
AU2003262262A1 (en)	2002-08-27	2004-03-19	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
DE10258008B4 (de) *	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ES2363941T3 (es)	2003-03-14	2011-08-19	Astellas Pharma Inc.	Derivados de c-glucósido para el tratamiento de diabetes.
ES2649737T5 (es)	2003-08-01	2021-07-07	Mitsubishi Tanabe Pharma Corp	Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
EA010655B1 (ru) *	2003-08-01	2008-10-30	Янссен Фармацевтика Н.В.	Замещенные индазол-о-глюкозиды
WO2005012243A2 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted indole-o-glucosides
CA2549015A1 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted fused heterocyclic c-glycosides
UA86042C2 (en) *	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
AU2004261663A1 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
MX2007003785A (es)	2004-09-29	2007-07-12	Kissei Pharmaceutical	Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008050353A (ja) *	2006-07-27	2008-03-06	Mitsubishi Tanabe Pharma Corp	医薬組成物

2007
- 2007-07-11 TW TW096125166A patent/TWI418556B/zh not_active IP Right Cessation
- 2007-07-25 JO JO2007306A patent/JO2681B1/en active
- 2007-07-25 UY UY30506A patent/UY30506A1/es unknown
- 2007-07-26 PE PE2007000981A patent/PE20080522A1/es not_active Application Discontinuation
- 2007-07-26 AR ARP070103316A patent/AR062111A1/es unknown
- 2007-07-26 CL CL200702197A patent/CL2007002197A1/es unknown
- 2007-07-26 US US11/878,760 patent/US7851617B2/en not_active Expired - Fee Related
- 2007-07-27 KR KR1020097004110A patent/KR101179312B1/ko not_active Expired - Fee Related
- 2007-07-27 BR BRPI0715369-4A patent/BRPI0715369A2/pt not_active IP Right Cessation
- 2007-07-27 DK DK07791887.8T patent/DK2049557T3/da active
- 2007-07-27 AT AT07791887T patent/ATE501159T1/de active
- 2007-07-27 NZ NZ574072A patent/NZ574072A/en not_active IP Right Cessation
- 2007-07-27 AU AU2007277662A patent/AU2007277662B2/en not_active Ceased
- 2007-07-27 WO PCT/JP2007/065213 patent/WO2008013322A1/en not_active Ceased
- 2007-07-27 EA EA200970161A patent/EA016819B1/ru not_active IP Right Cessation
- 2007-07-27 UA UAA200901760A patent/UA92100C2/uk unknown
- 2007-07-27 PL PL07791887T patent/PL2049557T3/pl unknown
- 2007-07-27 PT PT07791887T patent/PT2049557E/pt unknown
- 2007-07-27 MX MX2009000995A patent/MX2009000995A/es active IP Right Grant
- 2007-07-27 CA CA2658116A patent/CA2658116C/en not_active Expired - Fee Related
- 2007-07-27 CN CN2007800277313A patent/CN101501053B/zh not_active Expired - Fee Related
- 2007-07-27 DE DE602007013056T patent/DE602007013056D1/de active Active
- 2007-07-27 JP JP2009521499A patent/JP5102294B2/ja not_active Expired - Fee Related
- 2007-07-27 MY MYPI20090277A patent/MY145106A/en unknown
- 2007-07-27 EP EP07791887A patent/EP2049557B1/en active Active
2008
- 2008-12-19 NO NO20085337A patent/NO20085337L/no not_active Application Discontinuation
- 2008-12-30 IL IL196267A patent/IL196267A0/en not_active IP Right Cessation
2009
- 2009-01-22 GT GT200900014A patent/GT200900014A/es unknown
- 2009-01-26 CR CR10583A patent/CR10583A/es unknown
- 2009-01-26 HN HN2009000161A patent/HN2009000161A/es unknown
- 2009-01-27 CO CO09006937A patent/CO6150170A2/es unknown

Also Published As

Publication number	Publication date
PE20080522A1 (es)	2008-06-13
EP2049557B1 (en)	2011-03-09
UA92100C2 (uk)	2010-09-27
CA2658116C (en)	2011-07-19
MY145106A (en)	2011-12-30
DE602007013056D1 (de)	2011-04-21
KR20090040356A (ko)	2009-04-23
PT2049557E (pt)	2011-05-05
PL2049557T3 (pl)	2011-07-29
HN2009000161A (es)	2011-05-25
US7851617B2 (en)	2010-12-14
JO2681B1 (en)	2013-03-03
JP5102294B2 (ja)	2012-12-19
BRPI0715369A2 (pt)	2013-06-18
NO20085337L (no)	2009-04-24
ATE501159T1 (de)	2011-03-15
AR062111A1 (es)	2008-10-15
MX2009000995A (es)	2009-02-04
CN101501053B (zh)	2012-10-03
AU2007277662A1 (en)	2008-01-31
NZ574072A (en)	2011-05-27
CA2658116A1 (en)	2008-01-31
TW200811149A (en)	2008-03-01
CR10583A (es)	2009-06-05
KR101179312B1 (ko)	2012-09-03
WO2008013322A1 (en)	2008-01-31
CO6150170A2 (es)	2010-04-20
EP2049557A1 (en)	2009-04-22
UY30506A1 (es)	2008-01-31
CN101501053A (zh)	2009-08-05
AU2007277662B2 (en)	2011-02-03
US20080027122A1 (en)	2008-01-31
TWI418556B (zh)	2013-12-11
EA200970161A1 (ru)	2009-06-30
DK2049557T3 (da)	2011-06-14
CL2007002197A1 (es)	2008-02-15
JP2009544693A (ja)	2009-12-17
IL196267A0 (en)	2009-09-22
EA016819B1 (ru)	2012-07-30

Publication	Publication Date	Title
GT200900014A (es)	2010-02-09	Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.
NL1029016A1 (nl)	2005-11-15	Tetrahydronafthyridinederivaten.
NL2000627A1 (nl)	2007-11-12	Cycloalkylaminoderivaten.
DK1863818T3 (da)	2010-05-10	Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
NL2000323A1 (nl)	2007-06-21	Pyrimidine-derivaten.
DK1912991T3 (da)	2011-02-21	Xanthinderivater som selektive HM74A-Agonister
ATE481383T1 (de)	2010-10-15	3-aza-bicycloä3.1.0ühexanderivate
NL1031741A1 (nl)	2006-11-07	Purinederivaten.
NL2000537A1 (nl)	2007-09-24	Aminederivaten.
NL2000371A1 (nl)	2007-06-20	Chromaan gesubstitueerde benzimidazoolderivaten.
BRPI0718266A2 (pt)	2014-01-07	Compostos heterocíclicos como agentes anti-inflamatórios.
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
SI1998783T1 (sl)	2014-09-30	Oftalmični sestavki, ki obsegajo providon-jod
FR20C1027I2 (fr)	2021-06-11	Derives de tiglien-3-one
DK1846394T3 (da)	2012-01-16	Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
SMP200900065B (it)	2010-09-10	Derivati ciclizzati come inibitori di EG-5.
EA201000258A1 (ru)	2010-08-30	Новые гербициды
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.
BRPI0916363A2 (pt)	2018-05-29	derivados de 4,5-di-hidro-oxazol-2-ila
NL1030324A1 (nl)	2006-05-03	Sulfonylbenzimidazoolderivaten.
NL2000284A1 (nl)	2007-05-07	Pyrazine-derivaten.
DK1740569T3 (da)	2008-06-02	Imidazol-derivater som TAFla-inhibitorer